Homogeneous β-1,3-glucan / nucleic acid complex, and its applications
By refining β-1,3-glucan/nucleic acid complexes to have defined stoichiometric ratios and uniform lengths, the complexes achieve improved nucleic acid delivery efficiency and chemical homogeneity, suitable for pharmaceutical applications.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- NAPAJEN PHARMA
- Filing Date
- 2021-10-08
- Publication Date
- 2026-05-22
AI Technical Summary
Conventional β-1,3-glucan/nucleic acid complexes, such as SPG and poly(dA), are heterogeneous mixtures with varying molecular weights and nucleic acid contents, limiting their efficiency and chemical homogeneity, which is crucial for medical applications.
The development of low molecular weight β-1,3-glucan/nucleic acid complexes, specifically schizophyllan/poly(dA), is achieved through sonication, alkaline hydrolysis, and ultrafiltration to create homogeneous complexes with defined stoichiometric ratios of β-1,3-glucan to nucleic acid, forming a triple helix structure with uniform nucleic acid lengths and binding ratios.
The resulting homogeneous complexes exhibit enhanced nucleic acid delivery efficiency and chemical consistency, making them suitable for pharmaceutical use as carriers for introducing nucleic acids into cells.
Smart Images

Figure 0007863786000011 
Figure 0007863786000012 
Figure 0007863786000013